Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Frequently asked questions
What sector does Pharvaris BV (PHVS) operate in?
Pharvaris BV belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Pharvaris BV (PHVS) current stock price?
As of the latest data, Pharvaris BV stock price is $31.67, with a previous close of $31.54. Pharvaris BV gained $0.13 in the last trading session, representing a 0.41% increase.
What is Pharvaris BV (PHVS) current market capitalization?
Pharvaris BV market cap is approximately 2.22 billion.
What is Pharvaris BV (PHVS) Earnings Per Share (EPS)?
The trailing EPS is -$3.06, and the forward EPS is -$2.72.
What is Pharvaris BV (PHVS) EBITDA?
Pharvaris BV EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -57.81 million.
Does Pharvaris BV (PHVS) pay dividends?
No. Pharvaris BV does not pay a dividend.
When is Pharvaris BV (PHVS) next earnings report?
Pharvaris BV is expected to release its next earnings report on September 30, 2026.
What is Pharvaris BV (PHVS) beta (volatility) score?
Pharvaris BV has a beta of -2.461, indicating lower volatility than the overall market.
